Safety of canagliflozin in diabetic patients with chronic heart failure: randomized, non-inferiority trial

Trial Profile

Safety of canagliflozin in diabetic patients with chronic heart failure: randomized, non-inferiority trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms CANDLE
  • Most Recent Events

    • 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan.
    • 28 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top